FGF1 (OR 1.055, 95% CI: 1.005–1.107, P = .029) and FGF7 (OR 1.068, 95% CI: 1.007–1.133, P = .028) were consistently associated with increased risk of ER+ BC, however FGF20 (OR 0.959, 95% CI: 0.920–0.999, P = .046) decreased the risk of ER+ BC. Here, FGF20 is linked to breast cancer.